The introduction of immune checkpoint inhibitors such as Keytruda (Merck & Co.), Opdivo + Yervoy (Bristol Myers Squibb), and Tecentriq (Roche / Genentech; U.S. only), as well as BRAF / MEK inhibitor combinations such as Roche / Genentech’s Zelboraf plus Cotellic, Novartis’s Tafinlar plus Mekinist, and Pfizer / Array BioPharma’s Braftovi plus Mektovi, has significantly changed the treatment landscape for malignant melanoma in both the resectable and metastatic settings. Nonetheless, opportunities remain for novel agents specifically targeting the underrepresented BRAF wild-type unresectable or metastatic population. With the expected introduction of novel agents and combination regimens, the malignant melanoma treatment paradigm will continue to evolve.
Geographies: United States, EU5, Japan
Primary research: 16 country-specific interviews with thought-leading medical oncologists, supported by survey data collected for this and other Clarivate research
Epidemiology: incidence of malignant melanoma by country, segmented by BRAF mutation status, disease stage, and line of therapy
Forecast: 10-year, annualized, drug-level sales and patient share of key malignant melanoma therapies through 2032, segmented by brands / generics / biosimilars and epidemiological subpopulations.
Emerging therapies: Phase 3: 10 drugs; Phase 2: 2 drugs; coverage of select early-phase products.
Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.
Disease Landscape & Forecast will be updated throughout the year to provide timely insights and analyses as material indication-specific news and events unfold.
Disease Landscape & Forecast features a Drug Pipeline chapter with real-time, global pipeline intelligence content directly from Cortellis. This chapter is updated daily and features interactive figures that can be easily downloaded for detailed analysis or presentations.